Intellia.jpg
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
September 16, 2022 07:15 ET | Intellia Therapeutics, Inc.
Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses,...
Intellia.jpg
Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
September 16, 2022 07:00 ET | Intellia Therapeutics, Inc.
Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of...
22157.jpg
Worldwide CRISPR Industry to 2028 - by Application, End-user and Region
September 15, 2022 07:53 ET | Research and Markets
Dublin, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The "Global CRISPR Market 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global CRISPR market is anticipated to grow at a...
Global Genome Editing Market Report 2022: Continuous Technological Advancements in Gene-Editing Tools Driving Growth
August 29, 2022 05:53 ET | Research and Markets
Dublin, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The "Genome Editing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology, Application, and End User" report has been added to...
22157.jpg
Gene Therapy Market, 2035
August 09, 2022 07:53 ET | Research and Markets
Dublin, Aug. 09, 2022 (GLOBE NEWSWIRE) -- The "Gene Therapy Market by Type of Therapy, Type of Gene Delivery Method Used, Type of Vector Used, Target Therapeutic Areas, Route of Administration, and...
Straits Research Pvt Ltd
CRISPR Gene Editing Market Size is projected to reach USD 14.80 Billion by 2030, growing at a CAGR of 29.80%: Straits Research
August 01, 2022 12:40 ET | Straits Research
New York, United States, Aug. 01, 2022 (GLOBE NEWSWIRE) -- CRISPR Gene Editing, also called genome editing, modifies an organism's DNA. This method replaces, adds, or removes genetic material from...
Insights on the Genome Editing Global Market to 2027 - Growing Cases of Cancer and Other Genetic Disorders is Driving Growth
June 22, 2022 06:03 ET | Research and Markets
Dublin, June 22, 2022 (GLOBE NEWSWIRE) -- The "Genome Editing Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering. Genome editing is a method of making...
Intellia.jpg
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference
May 02, 2022 07:30 ET | Intellia Therapeutics, Inc.
Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell therapyFindings support recent development candidate...
Global CRISPR Technology Market Analysis 2022-2026, Featuring Profiles of Thermo Fisher Scientific, CRISPR Therapeutics, GenScript Biotech, Editas Medicine and Intellia Therapeutics
April 19, 2022 04:08 ET | Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "CRISPR Technology Global Market Report 2022, By Product Type, By Application, By End-User" report has been added to ResearchAndMarkets.com's offering....
Global Gene Editing Market Analysis 2022-2026, Featuring Profiles of CRISPR, GenScript, Thermo Fisher Scientific, Merck and AstraZeneca
April 19, 2022 04:03 ET | Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "Gene Editing Global Market Report 2022, By Technology, By End Users, By Application" report has been added to ResearchAndMarkets.com's offering. The...